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A comparative evaluation of
polytetrafluoroethylene, umbilical vein,
and saphenous vein bypass grafts for
femoral-popliteal above-knee
revascularization: A prospective
randomized Department of Veterans
Affairs cooperative study
Willard C. Johnson, MD,a Kelvin K. Lee, PhD,b and members of the
Department of Veteran Affairs COOP Study 141, Boston, Mass
Purpose: Currently, the choice of a vascular prosthesis for a femoral-popliteal above-knee
arterial bypass graft is left to the surgeon’s preference, because the available information
on comparative evaluations is inconclusive. The Department of Veterans Affairs (VA)
Cooperative Study 141 was established to identify whether improved patency exists with
different bypass graft materials for patients with femoral-popliteal above-knee bypass
grafts.
Methods: Between June 1983 and June 1988, 752 patients at 20 VA medical centers were
randomized to receive either an externally supported polytetrafluoroethylene (PTFE; N
= 265), human umbilical vein (HUV; N = 261), or saphenous vein (SV; N = 226) for
an above-knee femoral-popliteal bypass graft. The indication for the bypass grafting
operation was limb salvage in 67.5% of the patients. Patients were observed every 3
months for the first year and every 6 months thereafter. All patients were instructed to
take aspirin (650 mg) daily for the duration of the study.
Doppler-derived ankle-brachial indices (ABIs) were determined preoperatively and seri-
ally postoperatively. A bypass graft was considered to be patent when the Doppler-
derived postoperative ABI remained significantly improved (more than 0.15 units high-
er than their preoperative value) and additional objective information, such as
angiograms or operations, did not contradict these observations. Patency failure also
included bypass grafts that were removed because of an infection or aneurysmal degen-
eration. Patency rates were compared by using the Kaplan-Meier life table analysis.
Results: The cumulative assisted primary patency rates were statistically similar among
the different conduit types at 2 years (SV, 81%; HUV, 70%; PTFE, 69%). After 5 years,
above-knee SV bypass grafts had a significantly (P ≤ .01) better patency rate (73%) than
HUV bypass grafts (53%), which had a significantly (P ≤ .01) better patency rate than
PTFE bypass grafts (39%). Limb salvage was slightly worse with PTFE conduits. 
The number of bypass graft thromboses and major amputations within the first 30 days
was highest in the HUV group.
Conclusion: The overall results of this prospective randomized study suggest that the SV
should be considered as the bypass graft of choice for femoral-popliteal above-knee
reconstruction and that, when a prosthetic bypass graft is used, an HUV should also be
considered as an alternative choice to PTFE. (J Vasc Surg 2000;32:268-77.)
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In 1948, Kunlin1 pioneered the use of the saphe-
nous vein (SV) for femoral-popliteal (fem-pop)
above-knee (AK) bypass grafting procedures and
reported good results in individual patients. His
third patient had graft patency documented by
means of angiography for 27 years.2 The 5-year pri-
mary patency rate for fem-pop AK bypass grafts with
vein conduits ranges from 59% to 77%.3-9
In 1976, Campbell et al10 reported the first
North American experience with polytetrafluoroeth-
ylene (PTFE) bypass grafts; six were fem-pop AK,
and all remained patent (1 to 7 months of observa-
tion). Several reports suggest a long-term PTFE pri-
mary patency rate range of 42% to 63%.11-18
Dardik and Dardik19 first reported their early
experience with human umbilical vein (HUV)
bypass grafts in 1976. Several studies reported favor-
able patency rates for HUV fem-pop AK bypass
grafts, with long-term primary patency rate ranges of
61% to 75%.20,21 When the current clinical trial was
initiated, few comparative evaluations of HUV and
PTFE bypass grafts existed, and graft choice was
determined by surgeon preference. PTFE bypass
grafts were considered easier to use, whereas, even if
HUV bypass grafts had a slight patency advantage,
concern about the theoretical risk of aneurysmal
degeneration existed, limiting their use.
The Department of Veterans Affairs (VA)
Cooperative Study 141 was initiated to evaluate the
comparative efficacy of autogenous SV, externally
supported HUV, and externally supported PTFE
bypass grafts for fem-pop AK arterial reconstruction.
The observations of this clinical trial are the basis of
this report.
METHODS
At 20 VA medical centers, all patients scheduled
for a fem-pop AK bypass grafting procedure were
solicited for participation. Arterial ischemia was cat-
egorized as either disabling claudication or critical
ischemia (rest pain and tissue necrosis). Risk factors
that were prospectively recorded included the pres-
ence of diabetes mellitus, prior vascular reconstruc-
tion, heart disease, a history of a cerebrovascular
event, and smoking. Physical findings recorded were
peripheral pulses and Doppler pressure measure-
ments at the high-thigh, low-thigh, calf, and ankle
levels. The leg pressures were compared with the
higher brachial pressure to give the leg/brachial
index at these levels. Patients with noncompressible
vessels, with an ankle-brachial index (ABI) higher
than 0.9, or with a prior ipsilateral prosthetic fem-
pop AK or below-knee (BK) bypass graft were
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excluded. Patients with a prior ipsilateral SV bypass
graft were not excluded, but randomization was lim-
ited to either HUV or PTFE (stratum II). Other
exclusionary factors were emergency surgery, short
(less than 1 year) life expectancy, oral anticoagula-
tion, popliteal aneurysmal disease, a serum creati-
nine value higher than 2.0 mg/dL, polycythemia
(red blood cell count higher than 7.5 × 106/mm3),
and/or a platelet count higher than 106/mm2.
Patients were considered to be candidates for a fem-
pop AK bypass graft when they had good inflow to
the femoral artery, with an adequate distal popliteal
artery (< 50% stenosis) and at least one vessel out-
flow in either the tibial or peroneal vessels. Protocols
were approved by the local institutional review
boards, and informed consent was obtained from all
participants.
In stratum I, random assignment to either a
PTFE, HUV, or an ipsilateral SV bypass graft was
determined in the operating room. The randomiza-
tion was designed so that more of the patients would
be initially allotted an SV to adjust for the loss of
patients with an inadequate SV after operative dis-
section. When, after dissection, the vein was found
to be inadequate (less than 3.5 mm in external diam-
eter, varicose, phlebitic, or too short), the patient
was rerandomized to receive either an HUV or
PTFE graft and included in stratum II.
In stratum II, when the ipsilateral SV was not
“available” (prior excision, prior bypass grafting,
found inadequate when the participant was in stra-
tum I, or saved because of symptomatic coronary
artery disease), the choice between a PTFE and
HUV bypass graft was randomized in the operating
room. The PTFE bypass grafts (W.L. Gore,
Flagstaff, Ariz) were 6 mm “light weight” with
external support rings. The HUV bypass grafts
(Meadox Medicals, Cardiosurgery Division) were
either 6 mm or 5 mm in diameter. The HUV bypass
grafts were “flushed” with a heparin solution, as rec-
ommended by the manufacturer, before implanta-
tion. Composite or sequential bypass grafts were
excluded. Completion angiography was part of the
operative protocol. All patients were instructed to
take aspirin (650 mg/d) postoperatively for the
duration of the study, and all patients received 325
mg of aspirin the evening before surgery.
At each facility, a participating vascular surgeon
and a study coordinator were dedicated to the
enrollment and serial examination of study patients.
All operations were performed by either a vascular
resident or a senior general surgical resident, with
the direct participation and supervision of a staff vas-
cular surgeon. Postoperatively, the patients were
examined periodically for the current status of symp-
toms, pulses, and Doppler pressure determinations.
These examinations were performed on the first,
fifth, and 10th postoperative days and at the time of
hospital discharge. After discharge, patients were
seen every 3 months during the first year and every
6 months thereafter. Patients were terminated from
the study if they died, had an AK or BK amputation
with a patent bypass graft, or could not be located
for at least 12 months. All data were forwarded on
study forms to a central statistical center for com-
puter entry, storage, and analysis.
All patients were observed at all medical centers
until June 1989, when VA funding for this specific
study was terminated, as planned. However, other
VA-funded vascular cooperative studies at 12 VA
medical centers allowed for the continued observa-
tion (same follow-up protocol, study coordinator,
and vascular staff surgeon) of 153 of those 240 cur-
rently patent bypass grafts, until June 1991. For
patency analysis, the remaining 87 bypass grafts were
considered patent, but scored as “patent at last
observation” as of June 1989.
Bypass graft evaluation. Bypass grafts were
considered to be patent as long as the postoperative
ABI remained at least 0.15 higher than the preoper-
ative value,22,23 except when an occlusion was
demonstrated by means of operative findings or
angiography. A bypass graft with a transient low ABI
that on subsequent examinations demonstrated
patency was not scored as occluded. Patency rates as
reported in this analysis are cumulative “assisted pri-
mary” patency rates,24,25 because remedial surgery
for late bypass graft stenosis was not considered a
patency failure. The removal of a graft because of
infection or graft deterioration was considered to be
a bypass graft failure. Infection of a bypass graft was
considered present when poor incorporation of the
bypass graft, in the presence of erythema and persis-
tent drainage, was suggested by means of operative
findings. A culture negative for bacteria did not pre-
clude the diagnosis of infection. When a patient had
a sequential distal bypass graft or an AK or BK
amputation with a patent bypass graft, the study
bypass graft was considered patent until the date of
surgery and then withdrawn from observation.
Secondary patency rates after bypass graft thrombec-
tomy were not considered in this study.
Statistical analysis. The data analysis is based on
“intent to treat” (ie, patients were placed into the
bypass graft group to which they were randomized,
regardless of the bypass graft material actually
received). Bypass graft patency failure occurred
when a bypass graft occluded, became infected, or
developed aneurysmal changes that required opera-
tive intervention. Because the overall crude failure
rates of each prosthetic bypass graft between the
strata, with and without an available SV, were not
statistically different (25% with HUV and 31% with
PTFE in both strata), strata I and II graft perfor-
mances were combined for Kaplan-Meier analysis.
Kaplan-Meier life table analyses were performed on
the time-to-bypass-graft-failure data by using SAS
(SAS, Cary, NC) and BM.D.P software (BM.D.P
Statistical Software, Los Angeles, Calif). Proportions
and categorical-type data were compared with a χ2
test. Continuous data were compared with a Student
t test. All tests were two sided, and statistical signif-
icance was indicated by a P value of less than .05.
RESULTS
Patient population. Between June 1983 and
June 1988, 5854 patients were screened for inclu-
sion into VA Cooperative Study 141. After the ini-
tial screening, 2195 patients (37%) were still eligible.
Of these, 2039 patients signed the consent form,
and 1892 participated in this cooperative study. In
this paper, we report on the 775 patients who
received a fem-pop AK bypass graft and were 
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Fig 1. Life table analysis for the patency of saphenous vein
(V), human umbilical vein (H), and PTFE (P). N repre-
sents the number of bypass grafts being observed for
patency at that time.
randomized to receive either an externally support-
ed PTFE, HUV, or SV to bypass graft occlusion of
the superficial femoral artery. The remaining
patients participated in an evaluation of different
vascular prostheses for femoral-femoral and axillo-
femoral bypass grafting procedures26,27 and fem-pop
BK or femoral-tibial/peroneal bypass grafting pro-
cedures.28 During the course of this study, two cen-
ters (two cases) were replaced because of low
recruitment, and a third center was replaced when
the validity of the postoperative patency evaluations
was questioned. The data (six patients) from the lat-
ter center have been deleted from analysis on the
recommendation of the Data Monitoring Board.
The data on the two patients from the other two
centers were censored at the time of the last obser-
vation. After randomization, 17 patients (2.2%) were
excluded. The reasons included vessel calcification at
baseline (N = 6), the abandonment of planned
surgery (N = 3), prior participation in Cooperative
Study 141 (N = 5), a need to take Warfarin (N = 1),
patient ineligibility for VA benefits (N = 1), and
emergency surgery (N = 1). Therefore, 752 patients
constitute the study population. All patients at all
centers were observed until June 1989. At that time,
87 patients with patent bypass grafts in four centers
were withdrawn from observation because a VA-
funded coordinator was not available for data collec-
tion, whereas 153 patients with patent grafts were
observed until June 1991.
JOURNAL OF VASCULAR SURGERY
Volume 32, Number 2 Johnson et al 271
Table I. Baseline characteristics by graft material
Stratum I Stratum II
PTFE HUV SV PTFE HUV
Number of patients 122 115 226 143 146
Age (mean, y) 62 62 63 61 62
Diabetes mellitus 25% 35% 27% 39% 35%
Lower-limb amputation (contralateral AK, BK) 13% 12% 8% 15% 16%
Prior ipsilateral inflow procedure
Aorto-femoral/iliac bypass grafting 22% 18% 16% 18% 12%
Iliac percutaneous transluminal angioplasty 1.6% 1.7% 2.7% 2.7% 2.1%
Other (axillo-femoral, femoral-femoral, endarterectomy) 0.8% 2.6% 1.2% 6.4% 0.7%
Prior MI 23% 25% 22% 36% 36%
Prior coronary bypass graft 4% 6% 7% 13% 20%
Hypertension 51% 43% 46% 55% 57%
Prior strokes 16% 21% 12% 14% 24%
Tobacco use 98% 99% 98% 98% 97%
Significant alcohol consumption 33% 40% 42% 33% 47%
Contraindication to aspirin 4% 10% 11% 12% 8%
Reversed vein bypass grafting 84%
In situ bypass grafting 16%
Worst symptom
Claudication 34% 39% 41% 22% 26%
Rest pain 40% 37% 36% 38% 41%
Ischemic necrosis 26% 24% 23% 40% 33%
Baseline ABI 0.46 0.45 0.47 0.41 0.41
PTFE, Polytetrafluoroethylene; HUV, human umbilical vein; SV, saphenous vein; AK, above-knee; BK, below-knee; MI, myocardial
infarction; ABI, ankle-brachial index.
Table II. Perioperative morbidity (less than 30 d)
Fem-pop AK SV HUV PTFE
Number of bypass grafts 226 261 265
Mortality (%) 0.0 1.1 1.1
Wound complications (%) 9.3 6.9 6.1
BK or AK amputations (%) 0.4 2.7 0.4
Patency failure, 0 to 1 postop day 2 (0.88%) 12 (4.6%) 4 (1.51%)
Patency failure, 2 to 9 postop day 4 2 2
Patency failure, 9 to 30 postop day 5 18 0
Patency failure, 0 to 30 postop day 11 (4.87%)* 32 (12.26%)* 6 (2.26%)*
*P < .01 for SV versus HUV; P < .01 for PTFE versus HUV; P < .15 for SV versus HUV.
Fem-pop, Femoral-popliteal; PTFE, polytetrafluoroethylene; HUV, human umbilical vein; SV, saphenous vein; AK, above-knee; BK,
below-knee; postop, postoperative.
The baseline characteristics of the 752 patients in
this study are presented in Table I. The patients with-
in each conduit group in each stratum are homoge-
nous for the characteristics listed. The patients in stra-
tum II had as their prominent symptoms slightly
more cardiac disease, more peripheral vascular bypass
grafting procedures, and less claudication than
patients in stratum I. Twenty-seven patients (11%)
who were randomized to receive an SV graft in stra-
tum I had unusable veins and were rerandomized to
receive an HUV or PTFE graft in stratum II. These
27 patients were not scored as vein-failure patients.
The vein bypass grafts were reversed in 84% and 16%
in situ. Because of the nonavailability of bypass grafts
of sufficient length or surgeons’ reluctance, 10
patients received PTFE rather than HUV bypass
grafts (late bypass graft thrombosis developed in five
of these patients), and one patient received an HUV
rather than a PTFE bypass graft. Three patients incor-
rectly received an SV rather than an HUV bypass graft
because of an administrative error (late bypass graft
thrombosis developed in two of these patients). The
patency analysis was performed according to the orig-
inal randomization, intention to treat. A second
analysis by means of actual treatment did not change
the statistical significance of the results.
Early (less than 30 days) postoperative events.
The operative mortality rate was 0 in the SV group
and 1.1% in the HUV and PTFE groups. Wound
complications occurred in 9.3% of SV bypass grafts,
6.9% of HUV bypass grafts, and 6.1% of PTFE
bypass grafts. The incidence of failure during the first
30 postoperative days is reported in Table II. HUV
bypass grafts were at the highest risk (12.26%), which
was statistically greater than that for SV (4.87%; P ≤
.01), which was statistically similar to that for PTFE
(2.26%; P = .15). HUV bypass grafts had a higher
perioperative (first 24 hours) failure rate (4.6%) than
SV or PTFE grafts. Limb salvage was maintained by
means of thrombectomy (N = 9), a new bypass graft
(N = 19), or observation (N = 12) in 10 of 11 of the
SV, 25 of 32 of the HUV, and 5 of 6 of the PTFE
bypass grafts. Amputations were more frequent
(2.7%) in the HUV group (P ≤ .01).
Patient events (Table II). During the 8 years of
observation, 122 patients (16.3%) died with a patent
bypass graft. The median observation period before
death was 600 days. Sixteen patients (2.1%) were
withdrawn from patency observation at the time of
a major amputation (seven in the PTFE group, one
in the HUV group, four in the SV group) or sequen-
tial bypass grafting procedure (three in the HUV
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Table III. Patient events
SV HUV PTFE Total
Number of patients 226 261 265 752
Death with patent bypass graft (%) 14.6 14.9 18.9 16.2
Withdrawn (%) 6.2 5.0 4.9 5.3
Lost to follow-up (%) 10.2 8.8 11.3 10.2
Bypass graft failure (%) 22.6 37.2 41.1 34.2
Patent bypass graft at end of observation period (%) 46.4 34.1 23.8 34.2
BK or AK amputation (%) 8.4 9.6 12.5 10.2
PTFE, Polytetrafluoroethylene; HUV, human umbilical vein; SV, saphenous vein; AK, above-knee; BK, below-knee.
Table IV. Cumulative bypass graft performance: femoral-popliteal above-knee with saphenous vein
Number of patients Number of Number withdrawn % cumulative patency % SE of the
Interval (mo) entered failures patents at end of interval mean
0 to 6 226 22 18 89.8 2.1
6 to 12 186 16 11 84.3 2.5
12 to 18 159 2 15 83.2 2.6
18 to 24 142 4 18 80.7 2.8
24 to 30 120 1 9 80.0 2.9
30 to 36 110 4 12 76.9 3.1
36 to 42 94 0 18 76.9 3.1
42 to 48 76 2 15 74.7 3.4
48 to 54 59 1 11 73.3 3.6
54 to 60 47 0 8 73.3 3.6
> 60 39 4 35 – –
group, one in the SV group). Seventy-six patients
(10.2%) were lost to follow-up; the average patency
observation period in this group was 250 days.
Major amputations occurred more frequently (P =
.2) in the PTFE group (12.5%) than in either the
HUV (9.6%) or SV (8.4%) group.
Bypass graft performance. The assisted primary
patency rates are presented in Fig 1 and Tables IV, V,
and VI. A significant difference between bypass grafts
was present (P = .03). At 3 years, the superiority of
vein bypass grafts was apparent, whereas after 4 years,
the superiority of HUV bypass grafts, as compared
with PTFE bypass grafts, became apparent. Two
hundred fifty patients underwent a bypass grafting
procedure performed for only claudication, whereas
502 patients had their bypass grafting procedures
performed for critical ischemia. Table VII presents
the assisted primary patency rates for these different
subpopulations. A statistical difference existed
between bypass grafts for each subpopulation; how-
ever, this was not part of the primary statistical analy-
sis. In general, patients with claudication had a high-
er patency rate than patients with critical ischemia.
Six patients had late surgery for stenotic bypass
grafts (one in the HUV group, five in the SV
group). Five HUV and two PTFE bypass grafts
became infected while patent, and one HUV and
one PTFE bypass graft became infected after occlu-
sion had occurred. One SV and one HUV bypass
graft (at three different times and locations, 37, 41,
and 65 months) required operative intervention
(partial bypass graft replacement) for aneurysmal
disease. One SV sustained graft hemorrhage.
Aspirin treatment. Aspirin compliance, based
on pill counts and self-reporting, was documented at
each postoperative visit by the study coordinator.
Compliance was defined as having “consumed” at
least 50% of the expected number of pills. In gener-
al, approximately 90% of the patients were compli-
ant. No significant difference in compliance existed
among the patients with PTFE, HUV, and SV
bypass grafts.
DISCUSSION
This study is a randomized clinical trial evaluat-
ing three different vascular prostheses for fem-pop
AK arterial revascularization. Bypass graft assisted
patency rates were best for the SV, which was appar-
ent after 12 months. The prosthetic bypass grafts
had a similar performance for the first 24 to 30
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Table V. Cumulative bypass graft performance: femoral-popliteal above -knee with human umbilical vein
Number of patients Number of Number withdrawn % cumulative patency % SE of the
Interval (mo) entered failures patent at end of interval mean
0 to 6 261 58 25 76.6 2.7
6 to 12 178 6 11 73.9 2.8
12 to 18 161 3 13 72.5 2.9
18 to 24 145 5 12 69.8 3.0
24 to 30 128 3 14 68.1 3.1
30 to 36 111 7 18 63.5 3.4
36 to 42 86 3 11 61.1 3.5
42 to 48 72 3 7 58.4 3.7
48 to 54 62 1 12 57.4 3.7
54 to 60 49 3 15 53.2 4.2
> 60 31 7 24 – –
Table VI. Cumulative bypass graft performance: femoral-popliteal above-knee with polytetrafluoroethylene
Number of patients Number of Number withdrawn % cumulative patency % SE of 
Interval (mo) entered failures patent at end of interval the mean
0 to 6 265 34 38 86.0 2.2
6 to 12 193 19 22 77.0 2.8
12 to 18 152 9 11 72.2 3.0
18 to 24 132 5 12 69.4 3.2
24 to 30 115 8 13 64.2 3.4
30 to 36 94 9 14 57.6 3.7
36 to 48 71 9 9 49.8 4.0
48 to 54 53 5 9 44.7 4.2
54 to 60 39 5 5 38.6 4.4
> 60 22 4 18 – –
months, but thereafter the HUV bypass graft per-
formance was better than that of the PTFE graft.
Bypass graft performance was slightly better in the
claudication group than in those patients with criti-
cal ischemia (Table VII).
The failure rate of HUV bypass grafts during the
immediate postoperative period (4.6%) and for the
first 30 days (12.26%) was significantly higher than
that of SV or PTFE bypass grafts and may explain, in
part, the reluctance of some vascular surgeons to use
an HUV bypass graft. The HUV bypass graft is also
more difficult to use in successfully performing a
thrombectomy. The very low failure rate (2.26%)
and wound complication rate (6.1%) of PTFE bypass
grafts during the first 30 days may also explain why
the PTFE graft choice is frequently made in patients
who are candidates for fem-pop AK revasculariza-
tion. Patients can have a less-invasive operative pro-
cedure with good early patency and a lower risk of
wound complication, and the veins can be “saved for
another day.” In this study, 11% of potential patients
with an SV were found to have an unsatisfactory
vein. Oral anticoagulation has been proposed to fur-
ther improve the long-term patency of PTFE bypass
grafts.29
Comparison with earlier studies. In 1982,
Cranley and Hafner30 retrospectively reported their
long-term experience with HUV, as compared with
PTFE and SV, bypass grafts. For the 202 patients
with claudication and fem-pop revascularization, 92
HUV bypass grafts had a 36-month patency rate of
81%, compared with 88% in 64 SV bypass grafts and
65% in 46 PTFE bypass grafts. However, in patients
with limb-threatening ischemia and fem-pop revas-
cularization, 115 HUV bypass grafts had a 36-
month patency rate of 74%, as compared with 78%
in 73 SV bypass grafts and 41% in 73 PTFE bypass
grafts. In 1991, the New England Society of
Vascular Surgery Registry reported information on
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infrainguinal bypass grafts with PTFE and HUV.12
These data showed superior 5-year patency rates
with HUV (69% vs 45% in the AK position and 45%
vs 22% in the BK position). Several randomized
studies have been performed to comparatively eval-
uate the performance of HUV bypass grafts. Aalders
and van Vroonhoven31 reported in 1992 a 6-year
clinical trial of 96 patients (80% with claudication
alone) that compared PTFE and HUV in AK fem-
pop bypass grafting procedures. All patients were
treated with oral anticoagulation. This study showed
significantly higher cumulative patency rates for
HUV (75%) than for PTFE (34%). These numbers
were consistent with a Scandinavian randomized
prospective study by Eickhoff et al,32 in which HUV
had a better 3-year cumulative patency rate (42%)
than PTFE (22%) in the BK fem-pop bypass grafting
procedures in 104 patients.
In a trial from the United Kingdom, McCollum
et al33 reported higher (but not statistically differ-
ent) patency rates in a group of 191 patients, 68%
and 57% for HUV grafts at 1 and 3 years, respec-
tively, and 61% and 45% for PTFE grafts at 1 and 3
years, respectively. This trial did include both AK
(65%) and BK (35%) popliteal bypass grafts, and
these patients were treated with platelet-inhibiting
drugs. For patients with an AK bypass graft, each
prosthetic bypass graft had a similar 36-month
patency rate of 65%.
Veith and colleagues34 prospectively randomized
PTFE prosthetic bypass grafts and autogenous vein
bypass grafts in patients with critical ischemia and
showed a nonsignificant advantage with a saphenous
vein for fem-pop AK bypass grafts (4-year patency
rate, 68% vs 47%). Kumar et al35 reported a single-
site randomized study comparing SV with PTFE and
Dacron fem-pop bypass grafts in 145 patients with
claudication. His 4-year patency rates for SV and
PTFE bypass grafts were almost identical to those
Table VII. Cumulative assisted primary patency rate (%)
Cumulative assisted primary patency rate (%)
Number of patients 1 y 2 y 3 y 4 y 5 y
Claudication 250
SV 93 88 85 83 80 80
HUV 84 75 74 62 62 56
PTFE 73 75 70 60 48 33
Critical ischemia 502
SV 133 82 78 72 71 68
HUV 177 73 68 64 56 52
PTFE 192 78 69 57 43 37
PTFE, Polytetrafluoroethylene; HUV, human umbilical vein; SV, saphenous vein.
reported in the current study. Michaels36 performed
a meta-analysis of 1615 prosthetic bypass grafts
compared with 881 vein bypass grafts for fem-pop
AK revascularization; graft patency at 1 and 5 years
were 77% and 43%, respectively, with prosthetic
material, as compared with 80% and 62%, respec-
tively, for vein (P < .001).
Graft degeneration. Aneurysmal formation in
HUV bypass grafts has been noted in the extended
observation of HUV bypass grafts. Dardik et al20
have updated their experience with 907 HUV bypass
grafts, which suggests that “clinically significant”
aneurysms occur in only 6% of HUV bypass grafts
followed for 5 years. However, the results of duplex
ultrasonic evaluation of bypass grafts patent for more
than 5 years suggested that 25% had dilation of as
much as 9 mm and that an additional 36% were 1.0
cm or larger. Other authors have reported a similar
high prevalence of aneurysmal dilatation in HUV
bypass grafts that are patent for more than 5
years.37,38 However, Jarrett and Mahood39 found
that reoperations for aneurysmal changes were
required in only 3.3% of their 211 HUV fem-pop
bypass grafts. Aneurysmal rupture, however, has
been an extremely infrequent event. In this current
study, aneurysmal rupture did not occur in any
bypass graft. Anastomotic or bypass graft aneurysms
requiring operative intervention occurred in one SV
bypass graft, one HUV bypass graft, and in no PTFE
bypass graft. Because ultrasonic surveillance was not
part of this protocol, no further inference about the
frequency of graft dilatation can be made from the
present study. Recently, modifications have been
made in the support structure of the HUV bypass
graft.20 The original loosely woven mesh has been
replaced by a tighter weave of polyester, with the
intent of reducing the incidence of aneurysmal
changes; however, no data are available to support
the superiority of this new mesh.
CONCLUSION
The findings of this study suggest that, for the
first year, patency was similar for the different bypass
grafts. Thereafter, SV bypass grafts performed best.
The data also suggest that HUV bypass grafts may
be the better long-term prosthetic conduit, while
acknowledging that PTFE bypass grafts have a bet-
ter early performance.
The results of this study represent the findings in
an elderly subset of male patients who generally did
not have diabetes mellitus, who were smokers, and
who underwent surgery for critical ischemia or
severe claudication. The recommendations of bypass
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graft choice for other subsets of patients may need to
include other considerations, such as sex, age, or
patients with mild claudication.
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